NCT04787302View on ClinicalTrials.gov

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Schizophrenia
Interventions
DRUG

CVL-231

Cohort 1: 30mg dose of CVL-231

DRUG

CVL-231

Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded

DRUG

CVL-231

Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2

Trial Locations (2)

3000

UZ Leuven, Leuven

02114

Massachusetts General Hospital Translational and Clinical Research Centers, Boston

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT04787302 - PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing | Biotech Hunter | Biotech Hunter